The Coagulation Testing market size was valued at US$2,715.944 million in 2020 and is anticipated to increase at a Compound Annual Growth Rate of 4.16% over the predictive period to reach US$3,612.665 million by 2027. Coagulation Testing is done to examine blood disorders by testing the time it requires to form clots. Blood clots help in preventing excessive bleeding, by thickening and forming a layer to stop the blood flow. However, blood should not clot when it is flowing through the vessels, since such clots can travel to vital organs of the body and cause heart attacks, liver damage, or other serious illnesses. Therefore, to prevent the occurrence of any such casualty, a doctor may prescribe a coagulation test, to test the clotting ability of the blood.
Types of Coagulation Tests
Prothrombin time (PT or PT-INR): – Prothrombin is a protein produced by one’s liver and it helps in the clotting of blood. The prothrombin time (PT) test determines how quickly and effectively a person's blood clots. It usually takes between 25 and 30 seconds. If a person uses blood thinners, it may take longer. Hemophilia, liver illness, and malabsorption are among the other causes of abnormal readings. It can also be used to keep track of those who use blood thinners like warfarin (Coumadin).
The time it takes for the blood to clot is measured in seconds. When comparing findings from various laboratories, the PT test may utilize a computation termed the international normalized ratio (INR).
Fibrinogen Level: – Fibrinogen is another protein that is produced by the liver. This test determines the amount of fibrinogen in one's blood. Excessive bleeding or hemorrhage, fibrinolysis, or placental abruption, which is the removal of the placenta from the uterine wall, may report abnormal findings.
Platelet Count: – Platelets are blood cells that assist in the coagulation of blood. A platelet count may be prescribed by a doctor to determine the number of platelet cells in one's blood. A lower platelet count could lead to a risk of severe internal or external bleeding. A low platelet count may be reported if a person is on chemotherapy, using certain drugs, or has had a large blood transfusion. Celiac disease, vitamin K insufficiency, and leukemia are some other reasons for a low platelet count. A high platelet count could however potentially lead to heart diseases and disorders.
Thrombin Time: – Thrombin time is a measurement of how well a person's fibrinogen functions. Inherited fibrinogen abnormalities, liver illness, certain malignancies, and drugs that alter clotting can all cause unusual findings.
Bleeding Time: – A blood pressure cuff will be inflated and put on a person's upper arm. A handful of small incisions will be made on the lower arm by a healthcare practitioner. The wounds will be minor and not too deep. When the cuff has deflated, a healthcare professional will remove it and apply blotting paper to the cuts every 30 seconds until the bleeding stops. Bleeding lasts anywhere from one to nine minutes. The test is regarded to be safe, with few side effects or hazards. This test measures how quickly a person's skin blood vessels seal and stop bleeding.
The North American market has been reported to have the largest market share in the Coagulation Testing market. Owing to the increasing number of heart disease and diabetes cases, the market is expected to rise. According to the American Heart Association, cardiovascular diseases accounted for more than 850,000 deaths in the United States in 2019. Heart diseases have been reported to account for the highest number of deaths in the United States. Tobacco has also been reported as a leading cause of cardiovascular diseases in the United States. According to AHA, 23.6% of US high school students, and 6.7% of middle school students revealed that they use tobacco-based products in 2020. Moreover, the North American region has also seen significant growth in the number of diabetes cases in the region.
To address the growing number of cardiovascular and related diseases, government initiatives have been introduced in the region. Initiatives such as the Million Hearts 2022 are expected to control and prevent the increasing cases in the region. Million Hearts® 2022 is a five-year nationwide effort headed by the Centers for Disease Control and Prevention and the Centers for Medicare and Medicaid Services with the goal of preventing one million heart attacks and strokes in the next 5 years. The program concentrates partner initiatives on a limited number of issues that have been chosen for their impact on heart disease, stroke, and other illnesses.
Heart diseases also accounted for approximately 19.05 million global deaths in 2020. Tobacco has been reported to cause more than 8 million deaths worldwide, and with the increasing obesity and cardiovascular disease cases, this figure is expected to rise. Owing to the increasing medical expenditure and rapid developments in the healthcare industry, the coagulation testing market is expected to grow.
The COVID-19 pandemic resulted in a massive economical slowdown around the world. With most countries implementing lockdown protocols and social distancing norms, most major industries faced losses. Since most countries paid attention to controlling the virus outbreak, other medical segments suffered. Moreover, some countries even halted the non-essential testing and medical procedures, to utilize their resources in treating the infected patients. However, the market has been reported to be recovering. As most countries have lifted their lockdown protocols, the healthcare industry has seen an increase in the number of patients, which were not able to seek medical advice during the pandemic. Hence, the coagulation market is expected to increase in demand as countries and industries recover from the pandemic.